文献速递造血干细胞移植与细胞治疗血栓与止血

异基因干细胞移植后巨细胞病毒再激活的免疫控制

Immune control of cytomegalovirus reactivation in stem cell transplantation.
PubMed 文献 · Blood · 2022-01-01

本文综述异基因干细胞移植后巨细胞病毒(CMV)再激活的免疫控制机制。多能病毒特异性T细胞与保护相关,过继转移可防治再激活;NK细胞和树突状细胞分别参与早期监视和T细胞 priming;临床前模型显示毒株特异性体液应答可防早期再激活。抗病毒药物虽改善预后,但免疫学范式有望带来无毒持久的免疫治疗。

要点

  • 多能病毒特异性T细胞与CMV再激活保护相关,过继转移可防治再激活和疾病。
  • NK细胞参与早期病毒监视,树突状细胞参与T细胞 priming。
  • 临床前模型显示毒株特异性体液应答可预防早期CMV再激活。

核心结论

  • 理解移植后保护性抗病毒免疫的免疫学范式,有望开发无毒、基于免疫的持久保护策略。

研究设计与样本

  • 综述,总结异基因干细胞移植后CMV再激活免疫控制的相关证据。

主要发现

  • 多能病毒特异性T细胞与预防病毒再激活相关,过继转移病毒特异性T细胞可预防和治疗再激活及疾病。
  • NK细胞在早期病毒监视中发挥作用,树突状细胞在T细胞 priming 中发挥作用。
  • 临床前模型显示毒株特异性体液应答在预防早期CMV再激活中发挥作用。

临床怎么用

  • 抗病毒药物存在费用高、毒性及失败率问题,免疫学标志物和过继T细胞策略可辅助监测与防治。

局限性

  • 许多未知尚存:关键先天和适应性应答随时间的变化、应答来源和定位的重要性、GVHD及其防治对免疫轴的影响、控制潜伏/再激活/播散的免疫参数差异、新抗病毒药物对持久免疫的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The reactivation of viruses from latency after allogeneic stem cell transplantation (SCT) continues to represent a major clinical challenge requiring sophisticated monitoring strategies in the context of prophylactic and/or preemptive antiviral drugs that are associated with significant expense, toxicity and rates of failure. Accumulating evidence has demonstrated the association of polyfunctional virus-specific T cells with protection from viral reactivation, affirmed by the ability of adoptively transferred virus-specific T cells to prevent and treat reactivation and disease. The roles of natural killer cells in early viral surveillance and of dendritic cells in priming of T cells have also been delineated. Most recently, a role for strain-specific humoral responses in preventing early cytomegalovirus (CMV) reactivation has been demonstrated in preclinical models. Despite these advances, many unknowns remain: what are the critical innate and adaptive responses over time; are the origin (eg, recipient vs donor) and localization (eg, in parenchymal tissue vs lymphoid organs) of these responses important; how does graft-versus-host disease and the prevention and treatment thereof (eg, high-dose steroids) affect the functionality and relevance of a particular immune axis; do the immune parameters that control latency, reactivation, and dissemination differ; and what is the impact of new antiviral drugs on the development of enduring antiviral immunity. Thus, although antiviral drugs have provided major improvements over the past two decades, understanding the immunological paradigms underpinning protective antiviral immunity after SCT offers the potential to generate nontoxic, immune-based therapeutic approaches for lasting protection from viral reactivation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Degli-Esposti MA, Hill GR. Immune control of cytomegalovirus reactivation in stem cell transplantation. Blood. 2022. PMID: 34166512. doi:10.1182/blood.2020010028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。